AstraZeneca: Endometrial Neoplasms trials
The registry lists 17 Endometrial Neoplasms studies with AstraZeneca as lead sponsor. 9 are open to participants now and 2 have results posted.
Phase 1 6Phase 2 5Phase 3 4No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- DESTINY-PANTUMOUR04RecruitingNCT07124000
- Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)RecruitingNCT07044336Phase 3
- An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian FederationRecruitingNCT07041606
- Durvalumab With or Without Olaparib in Patients With Endometrial Cancers Regulatory Post Marketing SurveillanceRecruitingNCT06995833
- DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerRecruitingNCT06989112Phase 3
- NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)RecruitingNCT06890273
- Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid TumorsRecruitingNCT05797168Phase 1/2
- Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)RecruitingNCT05489211Phase 2
- A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesRecruitingNCT05123482Phase 1/2
- Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial CancerActive, not recruitingNCT04269200Phase 3Results posted
- Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.CompletedNCT00334295Phase 2Results posted
- ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid TumorsCompletedNCT06973161
- A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in SpainActive, not recruitingNCT06746116Phase 3
- Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid TumorsActive, not recruitingNCT06218914Phase 1
- Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesActive, not recruitingNCT04644068Phase 1/2
- A Phase 1 Study of [225Ac]-FPI-1434 InjectionTerminatedNCT03746431Phase 1
- Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment SchedulesCompletedNCT01226316Phase 1